|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | George Washington University |
|---|---|
| Information provided by: | George Washington University |
| ClinicalTrials.gov Identifier: | NCT00673244 |
Purpose
The principal objective is to safely determine if we can identify the severity of Acute Kidney Injury (AKI) early in the course of the disease. Once enrolled, we will draw blood and urine for relevant biomarkers. Our goal is to validate if any of these biomarkers can predict the course of AKI (recovery v. RRT v. death)
| Condition | Intervention |
|---|---|
|
ACute Kidney Failure |
Drug: Furosemide |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Protocol to Assess the Severity of Acute Kidney Injury |
| Estimated Enrollment: | 150 |
| Study Start Date: | April 2008 |
| Estimated Study Completion Date: | April 2012 |
| Estimated Primary Completion Date: | February 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Drug: Furosemide
One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
Other Name: Lasix
|
AKI is a very common disease in the intensive care unit. However, despite advances in supportive care, patients with AKI carry a high mortality rate (50% to 70%). The established AKI affects nearly 5 percent of hospitalized persons and as many as 15 percent of critically ill patients. Currently, there are no FDA approved therapeutic agents for the treatment of AKI.
Retrospective studies suggest that the early initiation of renal replacement therapy (RRT) improves outcome. Many clinicians tend to take a "wait and see" approach because they do not want to dialyze a patient who is destined to recover renal function without the need for RRT. Therefore, it is vitally important to know early in the course which patients with AKI are likely to progress to RRT.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Patients with a clinical syndrome consistent with pre-renal AKI
Patients with a clinical syndrome of post-renal AKI
Contacts and Locations| Contact: Lakhmir S Chawla, MD | 202-715-4570 | lchawla@mfa.gwu.edu |
| United States, District of Columbia | |
| George Washington University Hospital | Recruiting |
| Washington, District of Columbia, United States, 20037 | |
| Contact: Lakhmir S Chawla, MD 202-715-4570 lchawla@mfa.gwu.edu | |
| Principal Investigator: Lakhmir S Chawla, MD | |
| Principal Investigator: | Lakmir S Chawla, MD | George Washigton University |
More Information
| Responsible Party: | Lakhmir Chawla, GW Medical Faculty Associates |
| ClinicalTrials.gov Identifier: | NCT00673244 History of Changes |
| Other Study ID Numbers: | IRB# 010835 |
| Study First Received: | April 15, 2008 |
| Last Updated: | May 25, 2011 |
| Health Authority: | United States: Institutional Review Board |
|
Renal Replacement Therapy Dialysis |
|
Acute Kidney Injury Renal Insufficiency Kidney Diseases Urologic Diseases Furosemide Sodium Potassium Chloride Symporter Inhibitors Membrane Transport Modulators |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Diuretics Natriuretic Agents Physiological Effects of Drugs Cardiovascular Agents Therapeutic Uses |